.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD04_GlimepirideAndRosiglitaz.GlimepirideAndRosiglitaz .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD04_GlimepirideAndRosiglitaz.GlimepirideAndRosiglitaz| name: | GlimepirideAndRosiglitazone |
| ATC code: | A10BD04 | route: | oral |
| n-compartments | 1 |
Glimepiride and rosiglitazone is a fixed-dose combination of an oral sulfonylurea (glimepiride), which stimulates insulin secretion from pancreatic beta cells, and a thiazolidinedione (rosiglitazone), which improves insulin sensitivity in peripheral tissues. The combination is used for the management of type 2 diabetes mellitus in adults. The combination is approved for use in several countries, although rosiglitazone's approval status may vary due to cardiovascular safety concerns.
Estimated typical pharmacokinetic parameters for healthy adult subjects; individual PK studies generally report on monotherapy, as no published population PK model for the fixed-dose combination was identified.
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Vaidyanathan, J, et al., & Sahajwalla, CG (2012). Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. Journal of pharmaceutical sciences 101(5) 1659–1671. DOI:10.1002/jps.23085 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22383396
Plosker, GL, & Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 22(6) 389–411. DOI:10.2165/00019053-200422060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15099124